| ASBMT Best Abstract Awards for Basic Science |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Rhesus Macaque Natural CD4 Regulatory T Cells Exhibit Decreased Proliferation But Enhanced Suppression After Pulsing with Sirolimus
Although regulatory T cells (Tregs) suppress alloimmunity, difficulties in their large-scale production and in maintaining their suppressive function after expansion have so far limited their usefulne...
|
K. Singh,
L. Stempora,
A.D. Kirk,
C.P. Larsen,
B.B. Blazar,
L.S. Kean
et al.
|
S201
|
|
|
|
Gene Therapy for Hemophagocytic Lymphohistiocytosis (HLH): Fixing a Critical ‘Circuit Breaker’ in the Immune System
In addition to its well-known role in host defense, perforin-dependent cytotoxicity also has a critical immune regulatory function. Genetic defects of perforin underlie many cases of hemophagocytic ly...
|
M. Carmo,
P. Arumugam,
S. Tiwari,
A. Thrasher,
K. Risma,
P. Malik,
B. Gaspar,
M. Jordan
et al.
|
S201
|
|
|
|
Plasma Concentration of Suppressor of Tumorigenicity 2 (ST2), the IL33 Receptor, at Initiation of Graft Versus Host Disease Therapy Predicts Day 28 Response and Day 180 Survival Post-Treatment
Acute graft-versus-host disease (GVHD) is the primary limitation of allogeneic hematopoietic cell transplantation. Current diagnostic tests do not predict a patient's response to therapy, particularly...
|
M.T. Vander Lugt,
T. Braun,
J.L.M. Ferrara,
S. Hanash,
J.E. Levine,
C.-H. Wang,
Q. Zhang,
Q. Zhang,
A. Chin,
A. Harris,
S.W.J. Choi,
D. Couriel,
P. Reddy,
S. Paczesny
et al.
|
S201-S202
|
|
| CIBMTR Best Abstract Awards for Clinical Research |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Infusion of Non-HLA Matched, Off-the-Shelf Ex Vivo Expanded Cord Blood Progenitor Cells in Patients Undergoing Myeloablative Cord Blood Transplantation Is Safe and Decreases the Time to Neutrophil Recovery
With the goal of overcoming the significant delay in ANC recovery following cord blood transplantation (CBT), we have developed a clinically feasible methodology utilizing Notch ligand for ex vivo gen...
|
C. Delaney,
F. Milano,
H. Shelly,
I. Nicoud,
I.D. Bernstein
et al.
|
S203
|
|
|
|
CMX001 for Prevention and Control of CMV Infection in CMV-Seropositive Allogeneic Stem-Cell Transplant Recipients: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial of Safety, Tolerability and Antiviral Activity
CMX001, an oral Lipid-Antiviral-Conjugate, generates high intracellular levels of cidofovir-diphosphate. CMX001 has potent in vitro activity against dsDNA viruses including herpesviruses, adenoviruses...
|
F.M. Marty,
D. Winston,
S.D. Rowley,
M. Boeckh,
E. Vance,
G. Papanicolaou,
A. Robertson,
S. Godkin,
W. Painter
et al.
|
S203-S204
|
|
|
|
Overlap Subtype of Chronic GVHD Is Associated with Adverse Prognosis, Functional Impairment, and Inferior Patient Reported Outcomes: A Chronic GVHD Consortium Study
We examined whether overlap subtype of chronic GVHD was associated with different prognosis, functional limitations, or patient reported outcomes compared to “classic” chronic GVHD. Prospective data w...
|
J. Pidala,
G. Vogelsang,
P. Martin,
X. Chai,
B. Storer,
S. Pavletic,
D. Weisdorf,
M. Jagasia,
C. Cutler,
J. Palmer,
D. Jacobsohn,
S. Arai,
S.J. Lee
et al.
|
S204
|
|
| Oral Presentations |
| |
Article Title |
Author(s) |
Pages |
|
|
|
MGMT-Transduced γδ T Cells Function in the Presence of Temozolamide and Show Enhanced Cytotoxicity Against Temozolomide-Resistant High Grade Glioma Cell Lines: Potential Strategies for Combination of Chemotherapy and Immunotherapy
Treatment strategies for high-grade primary brain tumors such as glioblastoma multiforme (GBM) have failed to significantly and consistently extend survival. Recently, several studies have suggested t...
|
L.S. Lamb,
J. Bowersock,
A. Dasgupta,
G.Y. Gillespie,
H.T. Spencer
et al.
|
S205
|
|
|
|
Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of G-CSF in Lymphoma Patients Undergoing Autologous Stem Cell Collection
In Phase II and III trials, plerixafor has been combined with G-CSF and administered as a subcutaneous injection of 0.24 mg/kg, given 9-11 hours before pheresis. Intravenous (IV) administration of ple...
|
A. Cashen,
M. Rettig,
F. Gao,
T. Reineck,
C. Abboud,
K. Stockerl-Goldstein,
R. Vij,
G. Uy,
P. Westervelt,
J. DiPersio
et al.
|
S205
|
|
|
|
Complex Karyotype (CK) Is Associated with Increased Cumulative Incidence of Relapse (CIR) Following Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL) in First Remission
Complex cytogenetics predict patient outcomes and response to therapy in many hematologic malignancies, but there are few data regarding their significance in patients undergoing ASCT in MCL.
|
J.B. Cohen,
A.S. Ruppert,
L.D. Kaplan,
R. Baiocchi,
P. Porcu,
J. Flynn,
S. Penza,
J.A. Jones,
K.A. Blum,
S.M. Devine,
L.A. Andritsos
et al.
|
S205-S206
|
|
|
|
Maintained Hematologic and Organ Responses Following Risk Adapted Stem Cell Transplant (SCT) in Systemic Light-Chain Amyloidosis (AL) Using Bortezomib and Dexamethasone as Consolidation Therapy
Risk-adapted MEL dosing has improved the safety but may also compromise the efficacy of SCT for pts with AL. We report results of a phase II trial using bortezomib and dexamethasone (BD) as consolidat...
|
H.J. Landau,
H. Hassoun,
M.A. Rosenzweig,
C. Bello,
E. Hoover,
E. Riedel,
R.L. Comenzo
et al.
|
S206
|
|
|
|
Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity in Refractory or Poor-Risk Relapsed Non-Hodgkin'S Lymphoma (NHL) Patients Receiving an Autologous Stem-Cell Transplant (ASCT)
BEAM is considered a standard HDC regimen for ASCT for NHL. However, pts with primary refractory tumors (failure to achieve a CR to 1st-line treatment) or high-risk relapse have poor outcomes after BE...
|
Y. Nieto,
R.B. Jones,
U. Popat,
B. Andersson,
B. Valdez,
P. Thall,
E.J. Shpall,
C. Chancoco,
A. Alousi,
P. Anderlini,
C. Hosing,
M. Qazilbash,
Q. Bashir,
P. Kebriaei,
I. Khoui,
S. Ciurea,
S. Parmar,
G. Rondon,
R. Champlin
et al.
|
S206
|
|
|
|
Comparison of Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) with Beam and Busulfan/Melphalan (Bu/Mel) in Concurrent Cohorts of Refractory Hodgkin'S Lymphoma (HL) Patients Receiving an Autologous Stem-Cell Transplant
BEAM is considered a standard HDC regimen for pts with Hodgkin's lymphoma (HL) who are candidates for an ASCT. However, pts with primary refractory tumors or high-risk relapse have poor outcomes after...
|
Y. Nieto,
R.B. Jones,
P. Liu,
P. Anderlini,
U. Popat,
B. Andersson,
E.J. Shpall,
A. Alousi,
C. Hosing,
P. Kebriaei,
M. Qazilbash,
E. Frazier,
C. Chancoco,
Q. Bashir,
S. Ciurea,
S. Parmar,
R. Champlin
et al.
|
S206-S207
|
|
|
|
Higher Melphalan Exposure Is Associated with Improved Overall Survival for Myeloma Patients Undergoing Autologous Transplant
High dose melphalan (HDM) followed by autologous stem cell transplantation (ASCT) has a central role in the treatment of myeloma. We have already shown that patients given the same dose of HDM are exp...
|
P.J. Shaw,
C.E. Nath,
I. Nivison-Smith,
D.E. Joshua,
I.H. Kerridge,
P. Presgrave,
C.R. Tiley,
Y.L. Kwan,
J. Trotman
et al.
|
S207
|
|
|
|
Incidence of Cardiac Arrhythmias During Autologous Peripheral Blood Stem Cell Transplantation
Arrhythmias, especially supraventricular arrhythmias (SVA), often complicate autologous stem cell transplantation (ASCT). While easily treatable, they result in prolongation of hospital stay and incre...
|
A. Singla,
W.H. Hogan,
S.M. Ansell,
F.K. Buadi,
D. Dingli,
A. Dispenzieri,
D.A. Gastineau,
M.A. Gertz,
S.R. Hayman,
D.J. Inwards,
P.B. Johnston,
M.Q. Lacy,
M.R. Litzow,
I.N. Micallef,
L.F. Porrata,
S.K. Kumar
et al.
|
S207
|
|
|
|
B Cells from Patients with Chronic GVHD Signal Via the Akt-Driven Survival and Metabolic Fitness Pathway
Allogeneic hematopoietic stem cell transplant patients (HSCT) who develop chronic GVHD (cGVHD) have delayed B cell reconstitution despite persistently elevated plasma BAFF levels. High BAFF to B cell ...
|
J.L. Allen,
J. Wooten,
M. Fore,
N.S. Bhuiya,
P. Armistead,
J.M. Coghill,
D. Gabriel,
P.A. Roehrs,
A. Sharf,
R.N. Irons,
T. Hoffert,
K. Richards,
T.C. Shea,
A.S. Baldwin,
J. Serody,
S. Sarantopoulos
et al.
|
S207-S208
|
|
|
|
Phase II Pilot Study of Imatinib Mesylate for the Treatment of Severe Sclerotic Skin Chronic Graft Versus Host Disease (ScGVHD)
ScGVHD is characterized by progressive fibrosis of the dermis and subcutis and develops in 4-13% of patients with cGVHD. The clinical risk factors and mechanisms responsible for ScGVHD remain unclear;...
|
K. Baird,
S. Booher,
L.E. Comis,
G.O. Joe,
S.M. Steinberg,
S.D. Spencer,
W.D. Figg,
N. Takebe,
S.Z. Pavletic,
E.W. Cowen
et al.
|
S208
|
|
|
|
Targeted Janus Kinase-2 Inhibition Overcomes Limitations of Il6-Receptor-Alpha Blockade in Controlling Human DC-Stimulated Alloreactivity
Graft-versus-host disease (GvHD) is a serious challenge to the success of hematopoietic stem cell transplantation. The cytokine milieu of GvHD includes IL-6, IL-12, and IL-23, favoring Th1/Th17 differ...
|
B.C. Betts,
O. Abdel-Wahab,
S.A. Curran,
E.T. St. Angelo,
P. Koppikar,
M. Kennedy,
G. Heller,
R.L. Levine,
J.W. Young
et al.
|
S208-S209
|
|
|
|
HLA Matched Related Bone Marrow Transplantation in 85 Patients with Fanconi Anemia: The Brazilian Experience Using Cyclophosphamide 60Mg/Kg
Fanconi anemia(FA) is a rare disease characterized by progressive bone marrow failure, congenital anomalies and striking predisposition to cancer. BMT is indicated for pts who develop pancytopenia, my...
|
C. Bonfim,
L. Ribeiro,
M. Bitencourt,
J. Zanis-Neto,
A. Seber,
R. Gouveia,
R. Florencio,
A. Souza,
L. Daudt,
A.K. Vieira,
M. Ostronoff,
L.F. Bouzas,
R. Pasquini
et al.
|
S209
|
|
|
|
Impact of Chronic GVHD on Late Relapse, Treatment Related Mortality and Survival After Allogeneic Hematopoietic Cell Transplantation for Hematological Malignancies
Disease relapse remains a major obstacle to successful allogeneic hematopoietic cell transplantation (HCT). The development of chronic graft-versus-host disease (cGVHD) has been associated with fewer ...
|
M. Boyiadzis,
J.P. Klein,
M. Arora,
D.J. Weisdorf,
A. Hassebroek,
S.J. Lee,
M.E. Flowers,
C.S. Cutler,
A. Urbano-Ispizua,
J.H. Antin,
B.J. Bolwell,
J.-Y. Cahn,
M.S. Cairo,
R.P. Gale,
R.H. Herzig,
L.M. Isola,
D.A. Jacobsohn,
M.H. Jagasia,
T.R. Klumpp,
E.W. Petersdorf,
J.R. Wingard,
M.M. Horowitz,
S.Z. Pavletic
et al.
|
S209-S210
|
|
|
|
Priming of Hematopoietic Progenitor Cells (HPC) with Complement Fragment 3A (C3A) to Promote Homing of Umbilical Cord Blood (UCB): Safety Profile
Pre-clinical data showed that C3a priming of CD34+ HPC leads to activation of CXCR4, improved migration towards an SDF1 gradient, and faster hematopoietic recovery and better human engraftment in mice...
|
C.G. Brunstein,
D.H. Mckenna,
T.E. DeFor,
D. Sumstad,
M. Ratajczak,
M.J. Laughlin,
J.E. Wagner
et al.
|
S210
|
|
|
|
Impact of Hemochromatosis Gene (HFE) Polymorphisms and Iron Overload on Outcome of Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia
Iron overload is a common complication following hematopoietic stem cell transplantation (HSCT), and recent evidence suggests that it has an important influence on both morbidity and mortality. The C2...
|
J. Chakrabartty,
R. Krishna,
L.G. Balderamos,
C. Hunt,
A. Januszewski,
S. Ali,
I. Gabriel,
D. Marin,
J. Apperley,
B. Kishore,
J.M. Goldman,
R. Szydlo,
M. Busbridge,
K. Rezvani
et al.
|
S210
|
|
|
|
Expression of CD30 Is Increased on CD8+ T-Cells in Patients with Acute Graft-Vs-Host Disease
Acute graft-vs.-host disease (GVHD) remains a major source of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). CD30 is a cell surface membrane protein of the tumor ne...
|
Y.-B. Chen,
S. McDonough,
H. Chen,
J. Kennedy,
E. Coughlin,
M. Jagasia,
C. Cutler,
J. Ritz
et al.
|
S210
|
|
|
|
“No Wash” Albumin-Dextran Dilution for Double-Unit Cord Blood Transplantation (DCBT) Is Safe with Appropriate Management and Results in High Rates of Sustained Donor Engraftment
The wash of CB grafts involves additional product manipulation, risks cell loss, & delays time to infusion. We have previously reported that albumin-dextran dilution without centrifugation is feas...
|
P.B. Dahi,
M.N. Lubin,
K.L. Evans,
A.M.R. Gonzales,
A. Schaible,
J. Tonon,
G. Heller,
D.M. Ponce,
N.A. Kernan,
A. Scaradavou,
J.N. Barker
et al.
|
S211
|
|
|
|
Subsequent Hematopoietic Stem Cell Transplantation (HSCT) Associated with Longer Survival in Patients with Relapsed/Refractory (R/R) Acute Myelogenous Leukemia (AML) After Clo+Ara-C or Ara-C Alone: A Landmark Analysis from the Classic I Trial
We previously reported the efficacy/safety outcomes of the CLASSIC I study in older patients (pts) with R/R AML (Kantarjian, EHA 2011). In this report, we evaluate the outcomes of HSCT after Clo+Ara-C...
|
S. Ganguly,
H.M. Kantarjian,
M. Wetzler,
D. Rizzieri,
G. Schiller,
M. Hagasia,
R. Stuart,
D. Avigan,
M. Craig,
R. Collins,
M. Maris,
T. Kovacsovics,
S. Golberg,
K. Seiter,
P. Hari,
J. Greiner,
N. Vey,
C. Recher,
F. Ravandi,
E. Wang,
S. Eckert,
A. Partisano,
S. Faderl
et al.
|
S211-S212
|
|
|
|
Fludarabine and Cyclophosphamide (Flu-Cy) Based Conditioning Regimens Are Associated with Excellent Outcomes Especially in Low Risk Patients with Severe Aplastic Anemia (SAA)
One hundred and five patients (68 men and 37 women) with a median age of 20 years (range: 2 – 53) with SAA underwent related HLA identical stem cell transplantation (HSCT) using a conditioning regimen...
|
B. George,
V. Mathews,
R. Ahmed,
A. Abraham,
A. Srivastava
et al.
|
S212
|
|
|
|
The Novel 5-Group Cytogenetic Risk Classification of Myelodysplastic Syndrome (MDS), Monosomal Karyotype, and Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT)
The clonal karyotype is a major risk factor for the success of HCT in patients with MDS. Here we tested the relevance of the new 5-group cytogenetic risk classification and monosomal karyotype (MK) fo...
|
A. Gerds,
T. Gooley,
B.L. Scott,
F.R. Appelbaum,
H.J. Deeg
et al.
|
S212
|
|
|
|
Addition of Clofarabine to TLI/ATG Conditioning: Impact on Immune Reconstitution and Clinical Outcomes
The use of reduced intensity conditioning with total lymphocyte irradiation (TLI) and anti-thymocyte globulin (ATG) in preparation for allogeneic transplantation has been shown to minimize the risk of...
|
B. Glotzbecker,
H. Mills,
J. Rosenblatt,
R. Joyce,
J. Levine,
D. Tzachanis,
M. Stevenson,
E. Attar,
K. Ballen,
Y.-B. Chen,
V. Boussiotis,
J. Zwicker,
K. Luptakova,
J. Arnason,
J. Bonhoff,
C. Delaney,
K. Conway,
N. Giallombardo,
J. Mortellite,
D. Fitzgerald,
S. O'Brien,
C. McMahon,
B. Vasir,
D. Stroopinsky,
T. Spitzer,
D. Avigan
et al.
|
S213
|
|
|
|
Favorable Outcome of Hematopoietic Stem Cell Transplant in Severe Thalassemia Patients Older Than 10 Years by Using Reduced Intensity Conditioning Regimen
CIBMTR has reported that severe thalassemia patients who were older than 7 years and hepatomegaly, had poor outcome of transplantation (DFS = 55%) (Blood; 2011). We therefore would like to report our ...
|
S. Hongeng,
S. Pakakasama,
U. Anurathapan,
N. Sirachianan,
D. Songdej,
A. Chuansumrit
et al.
|
S213
|
|
|
|
Short-Term Immunosuppressive Agents for Graft-Versus-Host Disease (GVHD) Prophylaxis After Donor Lymphocyte Infusion (DLI) Have No Influence on Graft-Versus-Leukemia (GVL) Effects and Could Improve Leukemia-Free Survival in Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
The use of graft-versus-host disease (GVHD) prophylaxis after donor lymphocyte infusion (DLI) could reduce the incidence of severe DLI-associated acute GVHD in haploidentical hematopoietic stem cell t...
|
C. Yan,
D. Liu,
L. Xu,
H. Chen,
W. Han,
Y. Wang,
K. Liu,
X. Huang
et al.
|
S213
|
|
|
|
Allogeneic Stem Cell Transplantation for Korean Pnh Patients
PNH is a debilitating and life-threatening hematopoietic stem cell disorder characterized by chronic hemolysis leading to significant morbidities, end organ damage and mortality in PNH patients. Even ...
|
J.H. Jang,
J.W. Lee,
J.S. Kim,
S.S. Yoon,
J.H. Lee,
Y.K. Kim,
D.Y. Jo,
S.K. Sohn,
J.S. Chung
et al.
|
S213-S214
|
|
|
|
A Randomized Phase III Trial Investigating 2 Gy TBI Vs. Flu/2 Gy TBI Conditioning for HLA-Matched Related Donor Hematopoietic Cell Transplantation (HCT): Tempo of CD3 and NK Cell Engraftment Determines Relapse and Progression Free Survival in Patients with Hematologic
Nonmyeloablative conditioning with fludarabine (Flu) and 2 Gy TBI with MMF/CSP postgrafting immunosuppression results in reliable allogeneic engraftment. A retrospective analysis of pts conditioned wi...
|
B. Kornblit,
B. Storer,
R.F. Storb,
P. Hari,
V. Vucinic,
R.T. Maziarz,
T. Chauncey,
M.A. Pulsipher,
B. Bruno,
F.B. Petersen,
W.A. Bethge,
K. Hubel,
J. Storek,
D.G. Maloney,
B.M. Sandmaier
et al.
|
S214
|
|
|
|
Adenovirus Viremia in Patients with Clinical Symptoms After T-Cell Depleted HSCT: Rates of Adenovirus Disease and Outcomes
Invasive ADV infections are a known cause of mortality in HSCT. High or rising ADV viral loads are thought to be a predictor of ADV disease. T-cell depletion (TCD) reduces the risk of graft vs host di...
|
Y.J. Lee,
D. Chung,
K. Xiao,
T. Small,
E. Papadopoulos,
A.A. Jakubowski,
G.A. Papanicolaou
et al.
|
S214-S215
|
|
|
|
Coinfusion of Haplo-Identical Donor Stem Cells with an (Un)Related Cord Transplant Proved to Be Successful in a Very High Risk Group of Patients
Combining haplo-donor stem cells with a full graft cord blood (CB)-unit has been proposed as a cell support mechanism which can make single CB available as a donor source for allogeneic HSCT to a larg...
|
C.A. Lindemans,
J.H. Kuball,
L.C. te Boome,
A.B. Versluys,
M.B. Bierings,
J.J. Boelens
et al.
|
S215
|
|
|
|
CD8-Depleted Donor-Lymphocyte Infusions After T-Cell Depleted Allogeneic Hemopoietic Stem Cell Transplantation
In a phase I/II clinical trial, we investigated the prophylactic use of CD8-depleted (CD8depl) donor lymphocyte infusions (DLI) in the setting of T-cell depleted allogeneic hematopoietic stem cell tra...
|
E.M. Wagner,
D. Wehler,
K. Kolbe,
M. Theobald,
W. Herr,
R.G. Meyer
et al.
|
S215
|
|
|
|
Cord Blood Transplantation for Long Term Management or Possible Cure of HIV Infection
The most important mechanism for natural protection against HIV transmission is a mutation in the CCR5 gene leading to a 32-base-pair deletion (CCR5-delta32) and a non-functional CCR5 protein. Prior t...
|
L. Petz,
R. Tonai,
I. Redei,
S. Li,
H. Li,
Y. Bryson,
D. Regan,
S. Spellman,
L. Gragert,
M. Boo,
J. Gutman,
S. Armitage,
E. Shpall,
A. Lin,
J. Rosenthal,
J. Zaia,
J. Rossi,
J. Kurtzberg,
S. Forman,
R. Chow
et al.
|
S215-S216
|
|
|
|
Long Term Outcomes for Alemtuzumab Based Reduced Intensity Conditioning Transplant for Myelodysplastic Syndromes and Acute Myeloid Leukaemia
Haematopoietic Stem Cell Transplantation (HSCT) remains the only curative therapy for patients with myelodysplastic syndromes (MDS) and acute myeloid leukaemia with tri-lineage dysplasia (TLD-AML). Re...
|
V.T. Potter,
P. Krishnamurthy,
V.J. Tindell,
Z. Lim,
R. Ireland,
J.C. Marsh,
A. Pagliuca,
M.J. Ghulam
et al.
|
S216
|
|
|
|
Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis
The Myeloproliferative Disorder-Research Consortium (MPD-RC) designed the first US prospective phase II study of reduced intensity allogeneic hematopoietic stem cell transplantation (HSCT) in patients...
|
D. Rondelli,
J.D. Goldberg,
R. Marchioli,
L. Isola,
T.B. Shore,
J.T. Prchal,
A. Bacigalupo,
A. Rambaldi,
R.B. Klisovic,
V. Gupta,
B. Andreasson,
E.P. Demakos,
L.S. Price,
M. Scarano,
M. Wetzler,
A.M. Vannucchi,
V. Najfeld,
G. Barosi,
L.R. Silverman,
R. Hoffman
et al.
|
S216
|
|
|
|
Identification and Characterization of H-Y Specific Allogeneic B Cells Following Sex-Mismatched Transplantation
H-Y allo-antibody develop in association with chronic graft-versus-host disease (cGVHD) following sex-mismatched transplant. We hypothesize that H-Y specific B cells contribute to cGVHD pathogenesis a...
|
B. Sahaf,
S.H. Perloff,
F. Wu,
D.B. Miklos
|
S216-S217
|
|
|
|
Cytoreduction with Alemtuzumab in Patients with Advanced Chronic Lymphocytic Leukemia Prior to Allogeneic Stem Cell Transplantation – Results of a Prospective Clinical Trial (NCT 00337519)
The majority of patients (pts) with chronic lymphocytic leukemia (CLL) with an indication for allogeneic hematopoietic cell transplantation (HCT) suffer from refractory disease. Lower tumor load prior...
|
J. Schetelig,
M. Bornhäuser,
C. Thiede,
U. Platzbecker,
B. Mohr,
U. Oelschlägel,
M. Hänel,
R. Schwerdtfeger,
K. Kolbe,
M. Kaufmann,
M. Zeis,
K. Schäfer-Eckart
et al.
|
S217
|
|
|
|
Safety and Effectiveness of Intravenous Palivizumab for Prevention of Respiratory Syncytial Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplantation
Respiratory syncytial virus (RSV), a single-stranded RNA virus of the Paramyxoviridae family, is one of the most common causes of respiratory infections during childhood. Although most children are in...
|
T.N. Small,
N.A. Kernan,
F. Boulad,
S.E. Prockop,
A. Scaradavou,
R. Kobos,
N. Zakak,
J. Ruggiero,
R.J. O'Reilly
et al.
|
S217
|
|
|
|
Significance of Haplotype B Donors and Gene Content Motifs in Nonmyeloablative, HLA-Haploidentical (Haplo) Bmt with Posttransplantation High-Dose Cyclophosphamide (PT/Cy)
Killer immunoglobulin receptors (KIRs) regulate natural killer cell function, and can influence BMT outcome. We studied the relationship of KIR haplotype and gene content motifs in 208 patients who re...
|
H.J. Symons,
A.T. Munchel,
N.L. Rossiter,
Y.L. Kasamon,
R.J. Jones,
E.J. Fuchs,
M.S. Leffell
et al.
|
S218
|
|
|
|
Beneficial Effect of High-Dose Iv Busulfan (Bu) Delivered by Prolonged Continuous Infusion (CI) on Relapse Rate and Overall Survival (OS) in Matched Related and Unrelated Allogeneic Transplant Patients with Hematologic Malignancies
Dose escalation of chemotherapy and radiation in allogeneic transplant conditioning regimens has lowered relapse rates but not usually improved overall survival because of higher treatment related mor...
|
C. Walko,
A. Ivanova,
J. Whitley,
K. Rao,
D. Gabriel,
J. Serody,
T. Comeau,
J. Coghill,
P. Armistead,
S. Sarantopoulos,
W. Wood,
T. Shea
et al.
|
S218
|
|
|
|
Assessing Sleeping Beauty Transpositions for T-Cell Immunotherapy by Supercomputer-Based High-Throughput Profiling of Integration Events
Three first-in-human clinical trials using Sleeping Beauty (SB) transposition for immunotherapy of T cells expressing a CD19-specific chimeric antigen receptor (CAR) have received institutional and fe...
|
S.O. Ang,
S.N. Maiti,
B. Moriarity,
K. Andrews,
M. Ossowski,
K. Tzeng,
R. Talbot,
D. Kellar,
H. Huls,
P. Kebriaei,
S. Kelly,
E. Shpall,
D.A. Largaespada,
R. Champlin,
P.B. Hackett,
L.J.N. Cooper
et al.
|
S219
|
|
|
|
Factors Contributing to Viral Infections and the Limited Efficacy of Adoptively Transferred Donor Derived Immunodominant Virus-Specific T-Cells in Recipients of Haploidentical Stem Cell Transplants
HLA haplotype-disparate transplants are increasingly used for the treatment of patients lacking a matched donor. The high morbidity and mortality from serious viral infections (specifically CMV) has l...
|
A.N. Hasan,
E. Doubrovina,
L. Barnett,
S. Prockop,
R.J. O'Reilly
et al.
|
S219
|
|
|
|
Adoptive Transfer of Rapidly-Generated Multivirus-Specific T Cells to Treat Adenovirus, EBV and CMV Infections of Hematopoietic Stem Cell Transplant Recipients
We have demonstrated that small numbers of ex vivo-expanded, trivirus T cells, targeting EBV, CMV, and Adv are safe, proliferate in vivo and protect against all 3 viruses post-HSCT. However, broader i...
|
U. Gerdemann,
U.L. Katari,
J.M. Keirnan,
J.A. Craddock,
T.L. Dean,
H. Liu,
C.A. Martinez,
A.A. Kennedy-Nasser,
K.S. Leung,
S. Gottschalk,
A.O. Gee,
R.A. Krance,
M.K. Brenner,
C.M. Rooney,
H.E. Heslop,
A.M. Leen
et al.
|
S219
|
|
|
|
Human Papillomavirus Type 16 (HPV16) E6/E7-Specific Cytotoxic T Lymphocytes (CTLs) for Immunotherapy of HPV-Associated Malignancies
Vaccines prevent HPV-associated cancer (Ca), but their use as therapy for established Ca has been disappointing. Although the target tumor cells express the viral E6 and E7 antigens (Ag), patients' im...
|
C.A. Ramos,
N. Narala,
A.M. Leen,
U. Gerdemann,
M.L. Anderson,
E.M. Sturgis,
B. Savoldo,
H.E. Heslop,
M.K. Brenner,
C.M. Rooney
et al.
|
S220
|
|
|
|
Novel Therapy with Interferon-α in Combination with Donor Lymphocyte Infusion for High Risk Acute Leukemia Patients Who Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
In order to improve the graft versus leukemia (GVL) effect of DLI, we investigated the efficacy and safety of combining interferon-α with DLI (aDLI) in patients with high risk acute leukemia (AL) who ...
|
X. Tang,
Q. Zhou,
Z. Jin,
Z. Fu,
C. Ye,
X. Shi,
A. Sun,
D. Wu
et al.
|
S220
|
|
|
|
Salvage T Cell Therapy for Therapy Resistant Viral Diseases After Stem Cell Transplantation
Epstein-Barr virus (EBV), cytomegalovirus (CMV) and adenoviral reactivations are frequent complications after allogeneic SCT because of a lack of T cell control due to extensive immunosuppression. Cyt...
|
M. Uhlin,
J. Gertow,
M. Okas,
M. Uzunel,
M. Remberger,
J. Mattsson
et al.
|
S220-S221
|
|
|
|
Expression of α4β7 Integrin on Memory CD8+ T-Cells Is Increased in Patients at Presentation of Acute Intestinal Graft-Vs-Host Disease
Acute intestinal graft-vs.-host disease (GVHD) remains a major source of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). α4β7 integrin is a cell surface molecule tho...
|
Y.-B. Chen,
S. McDonough,
H. Chen,
J. Kennedy,
K.K. Ballen,
B.R. Dey,
S.L. McAfee,
T.R. Spitzer,
M. Jagasia,
J. Ritz
et al.
|
S221
|
|
|
|
Infusion of Syngeneic Apoptotic Cells Prior to Bone Marrow Transplantation Decreases Tcell Proliferation and Increases Survival
To prevent graft versus host disease (GVHD) the graft has to be rendered tolerant to avoid alloreactivity towards the host. One promising approach to induce tolerance is to administer apoptotic cells ...
|
M. Florek,
E.I. Sega,
A.M.S. Mueller,
D.B. Leveson-Gower,
J.A. Shizuru,
R.S. Negrin
et al.
|
S221
|
|
|
|
Low Levels of 25-Hydroxyvitamin D Prior to Allogeneic Transplantation Correlate with the Development of Chronic Graft-Versus-Host Disease
Graft-versus-host disease (GVHD) remains a significant cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation. GVHD is mediated by the activation and expansion o...
|
B.E. Glotzbecker,
V.T. Ho,
J. Aldridge,
H.T. Kim,
G. Horowitz,
J. Ritz,
R.J. Soiffer,
D. Avigan,
J. Rosenblatt
et al.
|
S221
|
|
|
|
Characterization of Outcomes After Secondary Systemic Treatment of Chronic Graft-Versus-Host Disease
Nearly 50% of patients with chronic graft-versus-host disease (GVHD) require secondary systemic treatment to control the disease. Outcomes after secondary treatment and the associated prognostic facto...
|
Y. Inamoto,
B.E. Storer,
S.J. Lee,
P.A. Carpenter,
M.E.D. Flowers,
P.J. Martin
et al.
|
S222
|
|
|
|
Extracorporeal Photopheresis: Effective Therapy for Steroid Dependent and Refractory Acute Graft-Versus-Host Disease
Outcome of patients (pts) with steroid refractory (SR) acute graft-versus-host disease (aGVHD) remains poor. We studied the efficacy and outcome of extracorporeal photopheresis (ECP) used as salvage t...
|
R.W. Jacobs,
M.H. Jagasia,
B.N. Savani,
A.T. Neff,
B.G. Engelhardt,
S. Goodman,
J.P. Greer,
K. Proctor,
F. Schuening,
N.H. Russell,
E. Das-Gupta
et al.
|
S222
|
|
|
|
α1 Anti-Trypsin (AAT-1), Augments DCs and Frequency of Regulatory T Cells (T reg), Modulates GVHD, and Increases Survival After Allogeneic Transplantation
Graft-versus-host disease (GVHD) is an important complication of allogeneic hematopoietic cell transplantation (HCT). We showed in a minor antigen mismatched murine transplant model that treatment wit...
|
A.M.Q. Marcondes,
M. Lesnikova,
G. Georges,
M. Mielcarek,
C.A. Dinarello,
H.J. Deeg
et al.
|
S223
|
|
|
|
The Impact of the Major Histocompatibility Complex Class I-Related Chain a (Mica) and Human Leukocyte Antigen (HLA)-DP Mismatches on Severe Acute GVHD in Patients Receiving Allogeneic Hematopoietic Progenitor Cell Transplants (AHPCT) from Adult Unrelated Donors
The role of matching for MICA and HLA-DP (DP) in AHPCT remains unclear. We investigate the impact of these mismatches (MM) on post-transplant outcomes.
|
M. Askar,
L. Rybicki,
A. Zhang,
D. Thomas,
M. Kalaycio,
E. Copelan,
B. Pohlman,
R. Dean,
H. Duong,
R. Hanna,
J. Maciejewski,
B. Bolwell,
R. Sobecks
et al.
|
S223
|
|
|
|
KIR3DL1/S1 and HLA-B Alleles Combine to Influence Unrelated Hematopoietic Stem Cell Transplantation (HSCT) Outcomes
NK cells play an important role in immunity against viruses and malignancy. Alleles for KIR3DL1/S1 are associated with improved outcome in HIV infection. Previous studies have shown differential impac...
|
F. Giglio,
J.M. Venstrom,
T.A. Gooley,
M.M. Gallagher,
T. Lebedeva,
H. Noreen,
R. Rajalingam,
E.F. Reed,
C. Vierra-Green,
N. Yu,
M. Haagenson,
S. Spellman,
M. Malkki,
E. Petersdorf,
K.C. Hsu
et al.
|
S223-S224
|
|
|
|
Haploidentical Bone Marrow Transplantation Using Anti-CD45 Radioimmunotherapy to Decrease Relapse in a Pre-Clinical Murine Model
Allogeneic hematopoietic cell transplant (HCT) is a widely used therapy for hematologic malignancy. It is important to give the option of HCT to patients without an HLA-matched donor; this is most acu...
|
A. Kenoyer,
J.J. Orozco,
D.K. Hamlin,
D.S. Wilbur,
D.R. Fisher,
M.D. Hylarides,
A. Axtman,
S.L. Frayo,
D.J. Green,
A.K. Gopal,
P. O'Donnell,
O.W. Press,
J.M. Pagel
et al.
|
S224
|
|
|
|
Early Post-Transplant Whole Tumor Cell-Based Vaccination Alters the Kinetics of T Cell Reconstitution
Whole tumor cell-based vaccines administered in the early post-transplant (HSCT) setting are a promising approach to enhance graft-versus-leukemia responses. Our previous studies described the detecti...
|
U.E. Burkhardt,
C. Desmarais,
H.S. Robins,
D. Wu,
J. Wong,
D. Neuberg,
E.P. Alyea,
R.J. Soiffer,
C.J. Wu
et al.
|
S224
|
|
|
|
Post-Transplant Cyclophosphamide (PT/Cy) Preserves Effector (Teff) and Regulatory (Treg) T Cells During Early Immune Reconstitution After Allogeneic Bone Marrow Transplantation
Emerging clinical data suggest that high-dose PT/Cy is effective in preventing both acute and chronic GVHD, but the mechanisms accounting for these effects have not been fully characterized. We hypoth...
|
C.G. Kanakry,
S. Ganguly,
F.J. Bolanos Meade,
M.L. Zahurak,
F. Kos,
E.J. Fuchs,
R.J. Jones,
A.D. Hess,
L. Luznik
et al.
|
S224-S225
|
|
|
|
Immune Insufficiency After Experimental Transplantation Is Due to Defective Antigen Presentation Within Dendritic Cell Subsets
Alloreactivity after transplantation is associated with profound immune suppression and consequent opportunistic infection results in high morbidity and mortality. This immune suppression is most dram...
|
K.A. Markey,
M. Koyama,
R.D. Kuns,
K.E. Lineburg,
Y.A. Wilson,
S.D. Olver,
A.L.J. Don,
A. Varelias,
R.J. Robb,
M. Cheong,
C.R. Engwerda,
R.J. Steptoe,
H.S. Ramshaw,
A.F. Lopez,
A.M. Lew,
J.A. Villadangos,
G.R. Hill,
K.P.A. MacDonald
et al.
|
S225
|
|
